Literature DB >> 32426211

COVID-19 pandemic: The experience of a multiple sclerosis centre in Chile.

Ethel Ciampi1, Reinaldo Uribe-San-Martin2, Claudia Cárcamo3.   

Abstract

Keywords:  COVID-19; Multiple sclerosis; Telemedicine

Year:  2020        PMID： 32426211      PMCID： PMC7229721          DOI： 10.1016/j.msard.2020.102204

Source DB:  PubMed          Journal:  Mult Scler Relat Disord        ISSN： 2211-0348            Impact factor:   4.339


× No keyword cloud information.
  5 in total

Review 1.  [EMCAM (Multiple Sclerosis Autonomous Community of Madrid) document for the management of patients with multiple sclerosis during the SARS-CoV-2 pandemic].

Authors:  L Costa-Frossard; I Moreno-Torres; V Meca-Lallana; J M García-Domínguez; En Representación Del Grupo de Estudio de Enfermedades Desmielinizantes de la Comunidad Autónoma de Madrid En Representación Del Grupo de Estudio de Enfermedades Desmielinizantes de la Comunidad Autónoma de Madrid
Journal:  Rev Neurol       Date:  2020-05-01       Impact factor: 0.870

2.  Treating multiple sclerosis and neuromyelitis optica spectrum disorder during the COVID-19 pandemic.

Authors:  Wallace Brownlee; Dennis Bourdette; Simon Broadley; Joep Killestein; Olga Ciccarelli
Journal:  Neurology       Date:  2020-04-02       Impact factor: 9.910

3.  An Italian programme for COVID-19 infection in multiple sclerosis.

Authors:  Maria Pia Sormani
Journal:  Lancet Neurol       Date:  2020-04-30       Impact factor: 44.182

4.  Digital triage for people with multiple sclerosis in the age of COVID-19 pandemic.

Authors:  Simona Bonavita; Gioacchino Tedeschi; Ashish Atreja; Luigi Lavorgna
Journal:  Neurol Sci       Date:  2020-04-17       Impact factor: 3.307

5.  The COVID-19 pandemic and the use of MS disease-modifying therapies.

Authors:  Gavin Giovannoni; Chris Hawkes; Jeannette Lechner-Scott; Michael Levy; Emmanuelle Waubant; Julian Gold
Journal:  Mult Scler Relat Disord       Date:  2020-03-27       Impact factor: 4.339
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.